Zymeworks (ZYME) Operating Margin (2021 - 2026)
Zymeworks recorded quarterly Operating Margin of 1956.73% in Q1 2026, down 11.46% quarter-over-quarter from 1755.55% in Q4 2025, and down 113050.0% year-over-year from N/an in Q1 2025.
Zymeworks' Operating Margin history runs 6 years deep, the most recent figure standing at 1956.73% for Q1 2026.
- In Q1 2026, Operating Margin fell 113050.0% year-over-year to 1956.73%; the TTM figure through Mar 2026 stood at 145.02% (up 6988.0% YoY), while the FY2025 annual figure was 87.34%, up 9235.0% from the prior year.
- Operating Margin came in at 1956.73% for Q1 2026 at Zymeworks, down from 1755.55% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 98.28% in Q4 2022 to a low of 3793.63% in Q1 2022.
- A 5-year average of 813.81% and a median of 376.89% in 2024 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin surged 371695 bps in 2023 and sank 168395 bps in 2025, its largest moves.
- Zymeworks' Operating Margin stood at 98.28% in 2022, then plunged by 241 bps to 138.37% in 2023, then jumped by 48 bps to 71.6% in 2024, then slumped by 2352 bps to 1755.55% in 2025, then retreated by 11 bps to 1956.73% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 1956.73%, 1755.55%, and 88.44% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | -1,956.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,956.73% |
| Dec 31, 2025 | -1,755.55% |
| Sep 30, 2025 | -88.44% |
| Jun 30, 2025 | -1.38% |
| Mar 31, 2025 | -826.23% |
| Dec 31, 2024 | -71.60% |
| Sep 30, 2024 | -213.78% |
| Jun 30, 2024 | -536.08% |
| Mar 31, 2024 | -376.89% |
| Dec 31, 2023 | -138.37% |
| Sep 30, 2023 | -201.36% |
| Jun 30, 2023 | -772.84% |
| Mar 31, 2023 | -76.68% |
| Dec 31, 2022 | 98.28% |
| Sep 30, 2022 | -1,914.03% |
| Jun 30, 2022 | -1,209.54% |
| Mar 31, 2022 | -3,793.63% |
| Dec 31, 2021 | -510.61% |
| Sep 30, 2021 | -1,387.12% |